Radiation therapy firm Varian Medical Systems is endorsing a phase III trial comparing the outcomes of radiosurgery and surgical resection for treating early-stage, high-risk, operable non-small cell lung cancer (NSCLC).
The Stablemates Trial is designed to compare three-year overall survival rates among patients with stage I NSCLC undergoing stereotactic ablative radiotherapy or conventional sublobar resection surgery.
Stereotactic ablative radiotherapy may provide patients with a noninvasive outpatient treatment option that is easier to tolerate and does not interfere with their normal, everyday activities, according to study co-chair Dr. Robert Timmerman from the University of Texas Southwestern Medical Center.
The trial currently includes 34 institutions and 258 patients.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
